CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Cohort I +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00895232
NCT00895232Phase 2Completed

Iron Sucrose In The Treatment of Restless Legs Syndrome (RLS): The Safety of Three Dose Regimens as Evaluated by Clinical Assessments

American Regent, Inc.·interventional·Posted May 8, 2009·Updated Nov 7, 2024

In Brief

A Phase 2 clinical trial evaluating Cohort I, Cohort II, and 1 other intervention for Restless Legs Syndrome. Completed, enrolled 21 participants.

Detailed Summary

Non-randomized open label Phase II clinical trial in which subjects meeting criteria for RLS were assigned to 1 of 3 treatment cohorts. The first cohort received one 500 mg IV iron sucrose infusion in 500 mL normal sterile saline (NSS) administered over four hours. The second cohort received two 500 mg IV iron sucrose infusions in 500mL of NSS administered over four to six hours on two separate dates, separated by two to seven days. The third cohort received two 500 mg IV iron sucrose infusions in at least 500 mL of NSS over six hours within 30 hours of the start of the first infusion. Cohorts were enrolled and treated subsequently.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 8, 2009
Enrollment StartNov 1, 2003
Primary CompletionAug 1, 2005
Study CompletionNov 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.2 years ago

Interventions

Cohort Idrug

Cohort IIdrug

Cohort IIIdrug